BCX5191

BCX5191 is an oral small molecule developed by BioCryst Pharmaceuticals. It has been characterized in different development contexts as both a nucleoside analog inhibitor of the Hepatitis C Virus (HCV) NS5B polymerase and as an oral plasma kallikrein inhibitor for the treatment of hereditary angioedema (HAE). In 2012, it was a central component of BioCryst's antiviral portfolio during a proposed merger with Presidio Pharmaceuticals, aimed at treating chronic HCV infection. Subsequently, licensing agreements with Shionogi & Co. identified BCX5191 alongside BCX4161 as a candidate for the prophylactic treatment of HAE. However, clinical development for these indications appears to have been discontinued as BioCryst shifted focus to other candidates such as berotralstat (BCX7353).